Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - DURECT Corporation (NasdaqNM:DRRX)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Location
10240 Bubb Road
Cupertino, CA 95014
Phone: (408) 777-1417
Fax: (408) 777-3577
Email: ir@durect.com
Employees (last reported count): 91
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 70%
·Institutional: 43% (143% of float)
(57 institutions)
·Net Inst. Buying: 1.54M shares (+6.98%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
DURECT Corporation is engaged in the treatment of chronic diseases and conditions by developing and commercializing pharmaceutical systems to deliver the right drug to the right place in the right amount at the right time. The Company's pharmaceutical systems combine engineering innovations and delivery technology from the medical device and drug delivery industries with its proprietary pharmaceutical and biotechnology drug formulations. By integrating these technologies, the Company is able to control the rate and duration of drug administration, as well as target the delivery of the drug to its intended site of action, allowing its pharmaceutical systems to meet the special challenges associated with treating chronic diseases or conditions. Its initial portfolio of products combines the DUROS technology, a patented drug delivery platform licensed for specified fields of use from ALZA Corporation, with drugs for which data on medical efficacy and safety are available.
More from Market Guide: Expanded Business Description

Financial Summary
DURECT Corporation is involved in the treatment of chronic diseases and conditions by developing and commercializing pharmaceutical systems to deliver the right drug to the right place in the right amount at the right time. For the six months ended 6/01, revenues totalled $3.1 million, up from $1.1 million. Net loss applicable to Com. totalled $25.9 million, up from $9.9 million. Results reflect the acquisition of the ALZET product line, offset by increased R&D activity.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Felix Theeuwes, 63
Chairman, CSO
$250K
James Brown, 44
Pres, CEO, Director
225K
Thomas Schreck, 43
CFO, Director
200K
Jean Liu, 32
VP, Legal Gen. Counsel
--  
Dennis Fisher, M.D.
VP, Medical Affairs
--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:DRRXAs of 31-Aug-2001
Price and Volume
52-Week Low
on 20-Mar-2001
$3.688
Recent Price$6.86 
52-Week High
on 7-Nov-2000
$16.375
Daily Volume (3-month avg)110.8K
Daily Volume (10-day avg)74.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y]
26-Week Change-0.2%
26-Week Change
relative to S&P500
+8.6%
Share-Related Items
Market Capitalization$329.3M
Shares Outstanding48.0M
Float14.4M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$2.37 
Earnings (ttm)-$1.29 
Earnings (mrq)-$0.45 
Sales (ttm)$0.14 
Cash (mrq)$1.43 
Valuation Ratios
Price/Book (mrq)2.90 
Price/EarningsN/A 
Price/Sales (ttm)48.32 
Income Statements
Sales (ttm)$5.16M
EBITDA (ttm)-$35.9M
Income available to common (ttm)-$36.9M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-35.08%
Return on Equity (ttm)-37.53%
Financial Strength
Current Ratio (mrq)13.27 
Debt/Equity (mrq)0.03 
Total Cash (mrq)$68.7M
Short Interest
As of 8-Aug-2001
Shares Short149.0K
Percent of Float1.0%
Shares Short
(Prior Month)
255.0K
Short Ratio1.46 
Daily Volume102.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.